AVITA Medical, Inc. (RCEL)
13.41
+0.31
(+2.37%)
USD |
NASDAQ |
Oct 15, 16:00
13.39
-0.02
(-0.15%)
After-Hours: 20:00
AVITA Medical Cash from Operations (TTM) : -24.71M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.71M |
| March 31, 2026 | -31.52M |
| December 31, 2025 | -31.76M |
| September 30, 2025 | -33.35M |
| June 30, 2025 | -35.42M |
| March 31, 2025 | -37.80M |
| December 31, 2024 | -48.36M |
| September 30, 2024 | -51.98M |
| June 30, 2024 | -52.96M |
| March 31, 2024 | -49.04M |
| Date | Value |
|---|---|
| December 31, 2023 | -37.25M |
| September 30, 2023 | -29.53M |
| June 30, 2023 | -23.28M |
| March 31, 2023 | -17.79M |
| December 31, 2022 | -18.09M |
| September 30, 2022 | -18.73M |
| June 30, 2022 | -25.99M |
| March 31, 2022 | -28.40M |
| June 30, 2021 | -26.75M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Halozyme Therapeutics, Inc. | 818.60M |
| Iovance Biotherapeutics, Inc. | -264.18M |
| Agenus, Inc. | -98.50M |
| Amgen, Inc. | 12.48B |
| Editas Medicine, Inc. | -119.86M |